Search
Zeling Bio Secures Nearly RMB 400 Million in Series B+ Funding
2025-08-05 /
Read about 0 minute
Author：小编
Chengdu Zeling Biomedicine Technology Co., Ltd. has recently announced the successful completion of a Series B+ funding round, raising approximately RMB 400 million. The investment was led by Qiming Venture Partners and will be directed towards accelerating multiple innovative drugs into pivotal Phase 3 clinical trials, as well as supporting the ongoing expansion of new research and development pipelines.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
